参附注射剂联合多巴胺治疗感染性休克患者的疗效及相关机制Effect of Shenfu injection combined with dopamine in treatment of septic shock and its related mechanism
朱仕兵,陈志明,王艳鹏,李志会,孙静,陆雅萍
摘要(Abstract)：
目的观察参附注射剂联合多巴胺治疗感染性休克患者的临床疗效,及对细胞免疫功能、心肌酶和细胞因子的影响。方法选择2015年3月至2017年3月ICU收治的感染性休克患者82例,按照随机数字表法分为对照组与观察组,各41例。对照组给予多巴胺2μg·kg~(-1)·min~(-1),iv gtt;观察组在对照组基础上静脉注射参附注射剂。疗程均为7d。结果观察组总有效率高于对照组(85.37%vs 60.98%,P<0.05)。2组治疗后心率、呼吸频率、APACHEⅡ评分及WBC均较治疗前降低(P<0.05),且观察组低于对照组(P<0.05)。2组治疗后CD3~+、CD4~+及CD4~+/CD8~+较治疗前升高(P<0.05),且观察组高于对照组(P<0.05)。2组治疗后CK-MB和cTnI较治疗前降低(P<0.05),且观察组低于对照组(P<0.05)。2组治疗后CRP较治疗前降低而IL-10较治疗前升高(P<0.05),且观察组CRP低于对照组而IL-10高于对照组(P<0.05)。结论参附注射剂联合多巴胺治疗感染性休克患者疗效显著,且可改善细胞免疫功能、心肌酶和细胞因子水平。
关键词(KeyWords)： 参附注射剂;多巴胺;感染性休克;疗效;细胞免疫功能;心肌酶
基金项目(Foundation):
作者(Author): 朱仕兵,陈志明,王艳鹏,李志会,孙静,陆雅萍
DOI: 10.19577/j.1007-4406.2018.02.004
参考文献(References)：
- [1]PAYEN DM,GUILHOT J,LAUNEY Y,et al.Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis:a multicenter randomized control trial[J].Intensive Care Med,2015,41(6):975.
- [2]LUIKING YC,POEZE M,DEUTZ NE.Arginine infusion in patients with septic shock increases nitric oxide production without haemodynamic instability[J].Clin Sci,2015,128(1):57.
- [3]支琳琳,冯伟,郭轶男,等.感染性休克患者不同时期液体负荷对机体影响的前瞻性临床研究[J].中华危重病急救医学,2015,27(1):13.
- [4]ZHANG Z,Ni H,QIAN Z.Effectiveness of treatment based on Pi CCO parameters in critically ill patients with septic shock and/or acute respiratory distress syndrome:a randomized controlled trial.[J].Intensive Care Med,2015,41(3):444.
- [5]HUBER W,HENSCHEL B,SCHMID RM,et al.Comments on Zhang et al.:Effectiveness of treatment based on Pi CCO parameters in critically ill patients with septic shock and/or acute respiratory distress syndrome:a randomized controlled trial[J].Intensive Care Med,2015,41(7):1389.
- [6]FANG XM,GAO Y,SHEN L,et al.Effect of ulinastatin combined with atomolam therapy on myocardial inflammatory injury and oxidative damage in patients with septic shock[J].Journal of Hainan Medical University,2016,22(24):21.
- [7]崔颖,戴琳琳.参附注射液治疗感染性休克疗效及对血流动力学的影响[J].现代中西医结合杂志,2016,25(19):2120.
- [8]刘波,平虎.去甲肾上腺素与多巴胺治疗感染性休克的比较研究[J].内科急危重症杂志,2014,20(1):30.
- [9]DELLINGER RP,LEVY MM,RHODES A,et al.Surviviing sepsis campaign:international guidelines for management of severe sepsis and septic shock:2012[J].Crit Care Med,2013,41(2):580.
- [10]MARIK PE.The demise of early goal-directed therapy for severe sepsis and septic shock[J].Acta Anaesthesiol Scand,2015,59(5):561.
- [11]GEER LD,ENGVALL J,OSCARSSON A.Strain echocardiography in septic shock-a comparison with systolic and diastolic function parameters,cardiac biomarkers and outcome[J].Crit Care,2015,19(1):1.
- [12]周建达.去甲肾上腺素与多巴胺治疗感染性休克的疗效比较[J].中国药房,2015,5(27):3794.
- [13]LI MQ,PAN CG,WANG XM,et al.Effect of the Shenfu injection combined with early goal-directed therapy on organ functions and outcomes of septic shock patients[J].Cell Biochem Biophys,2015,72(3):1.
- [14]钟恺立,江波.参附注射液治疗感染性休克疗效观察[J].医药前沿,2015,5(33):111.
- [15]马婷婷,胡兵伟,周程,等.感染性休克患者采用丙泊酚与依托咪酯麻醉对细胞免疫功能的影响研究[J].中华医院感染学杂志,2016,26(12):2682.
- [16]蔡伟红,罗红彤,郑伟萍,等.丙泊酚与依托咪酯麻醉对感染性休克患者细胞免疫功能的影响[J].中华医院感染学杂志,2012,22(13):2757.
- [17]程火星,谢庆.肌钙蛋白I和脑利钠肽联合检测在感染性休克相关心肌损伤诊治中的应用[J].河北医药,2016,38(7):1013.
- [18]谭兰婷,桂海波,杨桂香,等.心肌损伤标志物联合APACHEⅡ评分在感染性休克患者预后判断中的价值[J].中国急救医学,2015,13(5):385.
- [19]CARDOSO CP,DE OLIVEIRA AJ,BOTONI FA,et al.Interleukin-10 rs2227307 and CXCR2 rs1126579 polymorphisms modulate thepredisposition to septic shock[J].Mem Ins Oswaldo Cruz,2015,110(4):453.
- [20]方卫刚.C反应蛋白动态变化在感染性休克中的临床意义[J].内科急危重症杂志,2015,16(3):228.